Post-Approval Safety Issues with Innovative Drugs: A European Cohort Study-Reference-Cited by-同舟云学术

Post-Approval Safety Issues with Innovative Drugs: A European Cohort Study

Published:2013-09-19 Issue:11 Volume:36 Page:1105-1115
ISSN:0114-5916
Container-title:Drug Safety
language:en
Short-container-title:Drug Saf

Author:

Mol Peter G. M.,Arnardottir Arna H.,Motola Domenico,Vrijlandt Patrick J.,Duijnhoven Ruben G.,Haaijer-Ruskamp Flora M.,de Graeff Pieter A.,Denig Petra,Straus Sabine M. J. M.

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Pharmacology,Toxicology

Link

http://link.springer.com/content/pdf/10.1007/s40264-013-0094-y.pdf

Reference27 articles.

1. Califf RM. Benefit assessment of therapeutic products: the Centers for Education and Research on Therapeutics. Pharmacoepidemiol Drug Saf. 2007;16(1):5–16.

2. Arnardottir AH, Haaijer-Ruskamp FM, Straus SMJM, de Graeff PA, Mol PG. Safety issues of HIV drugs, regulatory consequences. Drug Saf. 2011;34(11):1101–14.

3. Stefansdottir G, Knol MJ, Arnardottir AH, van der Elst ME, Grobbee DE, Leufkens HG, et al. Safety learning from drugs of the same class: room for improvement. Clin Pharmacol Ther. 2012;91(5):872–80.

4. Motola D, De Ponti F, Poluzzi E, Martini N, Rossi P, Silvani MC, et al. An update on the first decade of the European centralized procedure: how many innovative drugs? Br J Clin Pharmacol. 2006;62(5):610–6.

5. Mol PG, Straus SM, Piening S, de Vries JT, de Graeff PA, Haaijer-Ruskamp FM. A decade of safety-related regulatory action in the Netherlands: a retrospective analysis of direct healthcare professional communications from 1999 to 2009. Drug Saf. 2010;33(6):463–74.

Cited by 28 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Evolution of Drug Regulatory Sciences in the Netherlands: More than a Country Report;Clinical Pharmacology & Therapeutics;2024-04-28

2. Factors associated with hematological adverse reactions of drugs authorized via the centralized procedure;Scientific Reports;2024-04-20

3. Association between Post-marketing Safety-related Regulatory Actions and Characteristics of New Drugs Approved in Japan between 2005 and 2016;YAKUGAKU ZASSHI;2022-07-01

4. Influence of drug safety advisories on drug utilisation: an international interrupted time series and meta-analysis;BMJ Quality & Safety;2022-01-20

5. Distribution- and Metabolism-Based Drug Discovery: A Potassium-Competitive Acid Blocker as a Proof of Concept;Research;2022-01